Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a First-in-Human Phase 1/2 Clinical Trial-Reference-Cited by-同舟云学术

Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a First-in-Human Phase 1/2 Clinical Trial

Published:2009-04 Issue:3 Volume:15 Page:171-181
ISSN:1071-9164
Container-title:Journal of Cardiac Failure
language:en
Short-container-title:Journal of Cardiac Failure

Author:

Jaski Brian E.,Jessup Mariell L.,Mancini Donna M.,Cappola Thomas P.,Pauly Daniel F.,Greenberg Barry,Borow Kenneth,Dittrich Howard,Zsebo Krisztina M.,Hajjar Roger J.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference48 articles.

1. Heart Disease and stroke statistics—2009 update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee;Lloyd-Jones;Circulation Epub,2008

2. Successes and failures of current treatment of heart failure;Cleland;Lancet,1998

3. Implantable left ventricular assist devices;Goldstein;N Engl J Med,1998

4. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure;Hajjar;J Card Fail,2008

5. Overwhelming evidence of the beneficial effects of SERCA gene transfer in heart failure;del Monte;Circ Res,2001

Cited by 381 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reversal of contractile defects by mediating calcium homeostasis in human mini-heart models of heart failure with preserved ejection fraction (HFpEF) leads to first-in-human gene therapy clinical trial;2024-08-28

2. Lower diastolic tension may be indicative of higher proarrhythmic propensity in failing human cardiomyocytes;Scientific Reports;2024-07-29

3. AAV-mediated gene therapy for sialidosis;Molecular Therapy;2024-07

4. CITED4 gene therapy protects against maladaptive cardiac remodeling after ischemia/reperfusion injury in mice;Molecular Therapy;2024-07

5. Exploring the Therapeutic Potential of Gene Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy;Biomedicines;2024-06-18